

## 2020 Market Analysis at Annual Alzheimers Congress

Holger Fröhlich


Professor, Department of Bioinformatics, University of Bonn, Germany, E-mail: holger.froehlich@ucb.com

Encouraged by the success of previous annual conferences in series, [Alzheimer's & Dementia Conference](#) Organizing Committee invites you to attend the largest assemblage of Neuroscientists, Neurological Surgeon, Neurologist, Neurophysiologist, Academic scientists, Neuro drug manufacturers, scholars from around the globe during [September 16-17, 2020](#) at [Edinburgh, Scotland](#). This is a phenomenal open door for the representatives from Universities and Institutes to connect with world-class Scientists. The main theme of the conference is **"Futuristic Approaches to shore up: Alzheimer's and Dementia Rehabilitation"**. This gathering will give a far-reaching update on all medicinal, surgical, interventional, and electrophysiological subjects and specialists with national and worldwide notoriety in different cardio sub-claims to fame will address the most recent rules, practice examples and arrangements in Neuropharmacology. Lectures will provide a comprehensive state-of-the-art update of the clinical uses of various techniques in the diagnosis, prognosis, and management of Alzheimer's and Dementia diseases.

Alzheimer's & Dementia is one of the greatest worldwide general wellbeing challenges confronting our age. Around the world, in any event, 44 million individuals are living with dementia this number is required to twofold by 2030 and more than triple by 2050 to 115 million. In 2011, an expected 747,000 Canadians were living with Alzheimer's or different dementias by 2031; it is assessed that 1.4 million Canadians will have dementia. In Canada 72% of Alzheimer's sufferers are ladies and 62% of dementia cases are likewise ladies. A significant part of the expansion will be in creating in nations like Western Europe and North America. Today, more than 35 million individuals worldwide as of now live with this condition. This number is relied upon to twofold by 2030 and more than triple by 2050 to 115 million. No medicines accessible to slow or stop the mind harm brought about by Alzheimer's ailment, a few prescriptions can briefly help improve the side effects of dementia for certain individuals. In two decades, it is

evaluated that 1.4 million Canadians will have dementia, costing the economy nearly \$300 billion every year. All around, dementia costs \$600 billion every year.


Percentage of the population aged 60 years or over, estimated for 1950-2014 and projected to 2050



Data source: United Nations (2013) World Population Prospects: The 2012 revision


Dementia is a form of disease that affects the functioning of the brain resulting in decline in memory or other thinking skills. Alzheimer's disease is the most common and largest form of dementia (in over 60% cases), which is observed among people aged 65 years and above. Accumulation of a protein called beta amyloid, in the spaces between nerve cells due to genetic mutation is a major cause of dementia. Although dementia disease is not treatable, symptomatic treatment is followed in all cases. Research is being carried out to develop treatment centered on the role of beta-amyloid in dementia.

The global dementia drugs market estimated to be valued at US\$ 13,900.0 million in 2017 and is expected to witness a CAGR of 8.4% over the forecast period (2018-2026).



## Alzheimer's disease and Therapeutic Market

Global Data estimated sales of AD therapeutics in 2016 to have been around \$3 billion over the seven major markets (7MM), which are the US, the five major European markets (5EU: France, Germany, Italy, Spain, and UK), and Japan. By 2026, Global Data foresees the AD market will have developed at a solid Compound Annual Growth Rate (CAGR) of 17.5%, arriving at sales of \$14.8 billion over the 7MM. This is mostly credited to the developing pervasiveness of both AD and mild cognitive impairment (MCI) and the quick take-up of biologics and other novel disease therapies (DMTs).



Alzheimer's has for quite some time been a prominent and consistently expanding medical issue in Thailand. The Ministry of Public Health (MoPH) reported that the quantity of Alzheimer's patients in Thailand is somewhat more than a half-million people. Leading neurologist at Bangkok Hospital Dr. Yotin Chinvarun shows that Alzheimer's is currently found in people

matured 40-65, where beforehand it was just pervasive in individuals more than 65. Today, there are roughly 2 million individuals in Thailand, who have been determined to have Alzheimer's.

The Alzheimer's Therapeutics Market is required to reach USD 12.43 Billion by 2026, as indicated by another report by Reports and Data. This can be essentially connected with the developing pipeline drug development, investment in biomarkers for drug development which are expected to further quicken the market development globally. Based on statistics, increase in advanced diagnostics for early identification, along with more scientific drug development, and emerging innovative diagnostics technologies are additionally a portion of the elements that are likewise developing the size of the worldwide market.

Geographically North America dominated global Multi-Infarct Dementia market, and Europe is projected to have fastest growth, while it is the most common type of dementia in Asia and other parts of the world. For instance, it accounts for more than 50% of dementia cases in Japan. The prevalence of multi-infarct dementia (MID) is expected to rise drastically in the near future given the exponential rise in geriatric population of the world. Therefore, the global multi-infarct dementia (MID) market is expected to grow rapidly in the developed nations such as the U.S., Canada, Germany, France, and Japan where there is enormous rise in the elderly people.